MedPath
FDA Approval

FUROSEMIDE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
November 9, 2020
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Furosemide(10 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Baxter Healthcare Corporation

005083209

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED

Baxter Healthcare Corporation

Baxter Healthcare Corporation

918603338

Products6

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

FUROSEMIDE

Product Details

NDC Product Code
36000-063
Application Number
ANDA202747
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
October 27, 2018
Code: 7LXU5N7ZO5Class: ACTIBQuantity: 10 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT

FUROSEMIDE

Product Details

NDC Product Code
36000-282
Application Number
ANDA202747
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
October 27, 2018
WATERInactive
Code: 059QF0KO0RClass: IACT
Code: 7LXU5N7ZO5Class: ACTIBQuantity: 10 mg in 1 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT

FUROSEMIDE

Product Details

NDC Product Code
36000-283
Application Number
ANDA202747
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
October 27, 2018
WATERInactive
Code: 059QF0KO0RClass: IACT
Code: 7LXU5N7ZO5Class: ACTIBQuantity: 10 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT

FUROSEMIDE

Product Details

NDC Product Code
36000-065
Application Number
ANDA202747
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
October 27, 2018
Code: 7LXU5N7ZO5Class: ACTIBQuantity: 10 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT

FUROSEMIDE

Product Details

NDC Product Code
36000-284
Application Number
ANDA202747
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
October 27, 2018
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
Code: 7LXU5N7ZO5Class: ACTIBQuantity: 10 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT

FUROSEMIDE

Product Details

NDC Product Code
36000-064
Application Number
ANDA202747
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
October 27, 2018
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
Code: 7LXU5N7ZO5Class: ACTIBQuantity: 10 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
© Copyright 2025. All Rights Reserved by MedPath